Sec Form 13G Filing - ADAR1 Capital Management, LLC filing for - 2026-02-17

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  Includes (i) 793,602 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 119,064 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of December 31, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 12,861,672 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of November 5, 2025, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Includes 793,602 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of December 31, 2025. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 12,861,672 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of November 5, 2025, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  Includes (i) 793,602 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 119,064 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of December 31, 2025. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 12,861,672 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of November 5, 2025, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.


SCHEDULE 13G


 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:02/17/2026
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:02/17/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:02/17/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

primary_doc.xml